Patient Age
% of patients with NDC vs Procedure Code
Patient Age
% of patients with NDC vs Procedure Code
seems to have more often then not an associated Days Supplied, but those with procedure codes rely on
Calculate their estimate weight from first claim date we observe. That should be closest to most normal dose
Patient Age
Add weight statistics and estimated dosing
atients Characteristics - 6 months CE Pre & 2 Post
Look at this population.
look at gaps between dosing that these patients are receiving alt. Do we have the time between dosing getting lower.
Claim Frequency
Can we add in Dosing information and Day supply
Data exploratio
There is interest into looking at the dosing for these patients. Let's look further into this data. @schuldtr
2 GBTM - Bucketing Trajectories into PDC Thresholds
PDC Thresholds:
90+, (Elmor developing rest)
Quartile_4
Highest cost
1-
Let's adjust this to two months.
Patient attrition table for 6-months pre CE
This seems to be the sweet spot. - Robert
Ocrevus loading dose: two Ocrevus claims 13 to 21 days apa
Add a table describing these patients.
Tables of Possible Cohorts - MS DX Only with and without washout
Look at who is and is not switching.
5 (1.5%) 2 (1.2%)
Crush Medicaid into Other Pay\er
2l34IbrutinibAnastrozole,IbrutinibAcalabrutinibAcalabrutinib,Anastrozole2l
Add notation here that If 2l then LOT2Linename == LOTENDS
Lot 1 Linename
Add any median
Mean Second Dos
Median IQR
Missing MG First Order
WIthin 45 Days N=
LL order details (13%, N=36 now represented in the table)
Updated to reflect 13% not N=13
osing Information on Venentoclax Patients
Arliene and Sophia: We only have 273 of our patients with a record in the Medication orders table. Not everyone is represented.
UGH
I am aware of typo I will update when I finish Sankey plot. As you can see this report takes 58 minutes to generate.
OD, N = 19,987,1801 OS, N = 19,940,3591
No need to break eyes.
5 Table 3 - Procedures Medication and Drug Tables
Only keep visits that match from Eye table. Check this.
N = 3,616,7511
Robert confirm if this is visits or patients
N of Patient Eyes (1 or 2 Treated)
David, here is the context. We have 83% of patients being treated for both eyes. That will mean that the N of injections probably appears higher since we aren't breaking them down into injections by specific eye.
Race/Ethnicity (Raw)
Possible project for Sophia? D&I - looking at disparities in ttt
VenG vs. Nibs - Tables & Curves - Two to One Match
Removed the 1:1 match - consolidated tables to be based on each matching pair.
2 Table 1 Characteristics
Overall Cohort - Moved everything descriptive of overall cohort to this first section
Our final sample size for the CLL FlatIron data set is 5,108 CLL patients fitting our inclusion and exclusion criteria.
Final sample size for our study
Dry AMD 43 (23%)
Is this an artifact of how they are recording the DX.
Showing 1 to 2 of 2 entries
Add in a count of the N of Study Patients and N of Sample Patients
Missing 0 (0%)
Missing added as a future proof option for future data uploads.
OU 0 (0%) Not Recorded 0 (0%)
When we filter out records for condition == ALL we lose all Not Recorded and OU records in the Eye table.
Unspecified
Patients with a race value, but it is not useful for analysis. I am considering this missing if we have unspecified. Do you want me to keep it like that?
Medicare Cost 497 (0.9%) 1,005 (1.8%) Medicare Risk 3,136 (5.4%) 4,952 (9.0%)
Slightly higher Medicare Cost and Risk patients in the Race/Ethnicity grouping. Possibly due to the older age
46 (36, 55) 50 (42, 58)
Fairly significant difference here. Not missing is older in comparison.
Months Enrollment Coverage 19 (12, 28) 24.3 (17.2, 29.4
Hmm this seems strange. Can you explain how this was calculated?
Age at Enspryng Initiation 47 (32, 55) 47 (30, 52)
Makes sense to me. Looks to be similar across cohorts
Ultimately, after consulting with my TI colleagues and reviewing what we need to do for variable follow-up, I believe that for ease of interpretability that we should use the 6 months CE pre patients only for this analysis.
Can you clarify?